ArticleMedicine and pharmacy reports2020
Diagnostic and prognostic value of microRNAs for Alzheimer's disease: a comprehensive meta-analysis.
Article in Medicine and pharmacy reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Human Leukocyte Antigen and microRNAs as Key Orchestrators of Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- MicroRNAs: A Novel Approach for Monitoring Treatment Response in Major Depressive Disorder?Non-coding RNA · 2025Review
- Dysregulated miRNAs in Progression and Pathogenesis of Alzheimer's Disease.Molecular neurobiology · 2022Review
- Nucleic acid liquid biopsies in Alzheimer's disease: current state, challenges, and opportunities.Heliyon · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsRecent research has shown that microRNAs (miRNAs), a class of sequences regulating gene expression without undergoing translational processes, have been accepted as novel biomarkers of diseases. In the present meta-analysis, our main objective was to evaluate the diagnostic value of miRNAs expressed in different body fluids for Alzheimer's disease (AD), more exactly to analyze the discriminative value of miRNAs between AD and control subjects.
methodsMedline and EMBASE were searched for articles written in English, and because the result reporting modalities were extremely different in the studies included in the analysis, the current article comprises 2 meta-analyses, each of them using different statistical indicators. The first meta-analysis reviewed 10 studies, which were required to provide sufficient information to allow the calculation of AUC or Cohen's d for size effect. We proposed a second meta-analysis, starting from the drawbacks identified in this first approach, which used different statistical indicators (fold change) provided by other studies (8 studies).
resultsThe present study offers an encouraging role of miRNA families in diagnosing AD. The heterogeneity of miRNA expression between the hippocampus, CSF and peripheral blood, the small sample size of each research study, as well as the different methods for miRNA detection remain the main obstacles in interpreting these results.
conclusionsThere is a need (in a future perspective) to establish the right miRNA combinations as potent diagnostic biomarkers for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.